JPWO2021001646A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021001646A5 JPWO2021001646A5 JP2021574936A JP2021574936A JPWO2021001646A5 JP WO2021001646 A5 JPWO2021001646 A5 JP WO2021001646A5 JP 2021574936 A JP2021574936 A JP 2021574936A JP 2021574936 A JP2021574936 A JP 2021574936A JP WO2021001646 A5 JPWO2021001646 A5 JP WO2021001646A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- nucleotide sequence
- double
- strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 34
- 125000003729 nucleotide group Chemical group 0.000 claims 34
- 102000039446 nucleic acids Human genes 0.000 claims 32
- 108020004707 nucleic acids Proteins 0.000 claims 32
- 150000007523 nucleic acids Chemical class 0.000 claims 32
- 229920002477 rna polymer Polymers 0.000 claims 31
- 230000002401 inhibitory effect Effects 0.000 claims 29
- 230000000692 anti-sense effect Effects 0.000 claims 19
- 108020004414 DNA Proteins 0.000 claims 18
- 102000053602 DNA Human genes 0.000 claims 18
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 12
- 108091081021 Sense strand Proteins 0.000 claims 5
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 3
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 102000052249 human APOB Human genes 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 claims 1
- 206010038378 Renal artery stenosis Diseases 0.000 claims 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 206010002906 aortic stenosis Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 230000009861 stroke prevention Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1909500.9A GB201909500D0 (en) | 2019-07-02 | 2019-07-02 | Antagonist |
| GB1909500.9 | 2019-07-02 | ||
| GBGB1910526.1A GB201910526D0 (en) | 2019-07-23 | 2019-07-23 | Antagonist |
| GB1910526.1 | 2019-07-23 | ||
| GB2000906.4 | 2020-01-22 | ||
| GBGB2000906.4A GB202000906D0 (en) | 2020-01-22 | 2020-01-22 | Antagonist |
| PCT/GB2020/051573 WO2021001646A2 (en) | 2019-07-02 | 2020-06-30 | Apolipoprotein b antagonist |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022537987A JP2022537987A (ja) | 2022-08-31 |
| JPWO2021001646A5 true JPWO2021001646A5 (https=) | 2023-07-07 |
| JP2022537987A5 JP2022537987A5 (https=) | 2023-07-07 |
| JP7463410B2 JP7463410B2 (ja) | 2024-04-08 |
Family
ID=71949646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021574936A Active JP7463410B2 (ja) | 2019-07-02 | 2020-06-30 | アポリポタンパク質ｂアンタゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230027604A1 (https=) |
| EP (1) | EP3965781A2 (https=) |
| JP (1) | JP7463410B2 (https=) |
| CN (1) | CN114072503A (https=) |
| CA (1) | CA3143404C (https=) |
| GB (1) | GB2585278B (https=) |
| WO (1) | WO2021001646A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202020534D0 (en) * | 2020-12-23 | 2021-02-03 | Argonaute Rna Ltd | Conjugate |
| US20250304966A1 (en) * | 2020-12-23 | 2025-10-02 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| WO2023041508A2 (en) * | 2021-09-14 | 2023-03-23 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| GB2618915B (en) * | 2022-05-18 | 2024-08-14 | Argonaute Rna Ltd | Treatment of cardiovascular disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7528118B2 (en) * | 2004-09-24 | 2009-05-05 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of ApoB and uses thereof |
| US8067572B2 (en) * | 2005-05-25 | 2011-11-29 | The University Of York | Hybrid interfering RNA |
| EP2105145A1 (en) * | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
| US8236943B2 (en) * | 2009-07-01 | 2012-08-07 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein B |
| US20150025122A1 (en) * | 2009-10-12 | 2015-01-22 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
| US10264976B2 (en) * | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| KR20230043114A (ko) * | 2020-06-24 | 2023-03-30 | 사프렘 테크놀로지스 비.브이. | Galnac과 사포닌의 접합체, 상기 접합체 및 galnac-올리고뉴클레오티드 접합체를 포함하는 치료적 조성물 |
| US20250304966A1 (en) * | 2020-12-23 | 2025-10-02 | Argonaute RNA Limited | Treatment of cardiovascular disease |
-
2020
- 2020-06-30 US US17/620,973 patent/US20230027604A1/en not_active Abandoned
- 2020-06-30 CN CN202080048130.6A patent/CN114072503A/zh active Pending
- 2020-06-30 JP JP2021574936A patent/JP7463410B2/ja active Active
- 2020-06-30 WO PCT/GB2020/051573 patent/WO2021001646A2/en not_active Ceased
- 2020-06-30 CA CA3143404A patent/CA3143404C/en active Active
- 2020-06-30 EP EP20751621.2A patent/EP3965781A2/en active Pending
- 2020-06-30 GB GB2010004.6A patent/GB2585278B/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2487716C2 (ru) | Новые структуры малых интерферирующих рнк (sirna) | |
| ATE460481T1 (de) | Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung | |
| WO2023041508A3 (en) | Treatment of cardiovascular disease | |
| JP2018530529A5 (https=) | ||
| RU2007134212A (ru) | Аптамерные терапевтические средства, применимые для лечения связанных с комплементом расстройств | |
| RU2011130434A (ru) | Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний | |
| JP2006500958A5 (https=) | ||
| Fukusaki et al. | DNA aptamers that bind to chitin | |
| JP2003503355A5 (https=) | ||
| JP2005517412A5 (https=) | ||
| WO2005030960A1 (ja) | ステイプル型オリゴヌクレオチドおよびそれからなる医薬 | |
| JP3721308B2 (ja) | より良好な安定性及びアンチセンス効果を有する新規なアンチセンス−オリゴ | |
| JPWO2021001646A5 (https=) | ||
| US20110076251A1 (en) | Novel therapeutic agents against hepatitis | |
| FI930627A0 (fi) | Modulering av celladhesion med oligonukliotider | |
| JP2011511776A (ja) | ＲＮＡ干渉のためのカチオン性ｓｉＲＮＡ、合成及び使用 | |
| JPWO2021167841A5 (https=) | ||
| Zavyalova et al. | DNA aptamer-based molecular nanoconstructions and nanodevices for diagnostics and therapy | |
| JPWO2023041508A5 (https=) | ||
| EP3286331B1 (en) | Method for hybridizing a nucleic acid molecule | |
| US20130028957A1 (en) | Pharmaceutical composition for treating cancer | |
| JP2007517498A5 (https=) | ||
| JPWO2022136673A5 (https=) | ||
| Esteban et al. | The impact of rapid evolution of the hepatitis viruses | |
| JPWO2007072909A1 (ja) | 新規オリゴヌクレオチド及びそれから成るＮＦ−κＢデコイ |